A 29-year-old woman was referred to Tufts Medical Center for undifferentiated bilateral anterior and intermediate uveitis.The ...
Roivant Sciences Ltd. (NASDAQ:ROIV) is a clinical-stage biopharmaceutical company that discovers, develops, and ...
Zacks.com on MSN
Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback